View Agent
| Agent Info | |
| Agent: | lenvatinib |
| Synonyms: | Lenvatinib;Lenvima;E-7080;ER-203492-00 |
| Drug Status For Certain Diseases: | Locally-recurrent or metastatic radio-iodinerefractory differentiated thyroid cancer(approved) |
| Classification: | an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 through 3 (VEGFR1-VEGFR3), fibroblast growth factor receptors 1 through 4 (FGFR1-FGFR4), platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks implicated in tumor angiogenesis |
| Target: | Alpha platelet-derived growth factor receptor Mast/stem cell growth factor receptor Proto-oncogene tyrosine-protein kinase receptor ret VEGF receptor Fibroblast growth factor receptor |
| KEGG Pathway: | Ras signaling pathway Endocytosis Melanogenesis Transcriptional misregulation in cancer Pathways in cancer PI3K-Akt signaling pathway Rheumatoid arthritis Hematopoietic cell lineage Acute myeloid leukemia Central carbon metabolism in cancer Thyroid cancer Rap1 signaling pathway Cytokine-cytokine receptor interaction |
| Wiki Pathway: | SIDS Susceptibility Pathways miR-targeted genes in epithelium - TarBase miR-targeted genes in muscle cell - TarBase Differentiation Pathway Cardiac Progenitor Differentiation Kit receptor signaling pathway Signaling by PDGF Integrated Pancreatic Cancer Pathway Dopaminergic Neurogenesis miR-targeted genes in lymphocytes - TarBase Signaling by SCF-KIT PIP3 activates AKT signaling Osteoblast Signaling Angiogenesis Signaling Pathways in Glioblastoma Allograft Rejection Hair Follicle Development Focal Adhesion Regulation of Actin Cytoskeleton |